Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcγRI, FcγRIII, and FcγRIV
V Minard-Colin, Y Xiu, JC Poe… - Blood, The Journal …, 2008 - ashpublications.org
Despite the demonstrated clinical efficacy of CD20 monoclonal antibody (mAb) for
lymphoma therapy, the in vivo mechanisms of tumor depletion remain controversial and …
lymphoma therapy, the in vivo mechanisms of tumor depletion remain controversial and …
The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor–dependent mechanisms during anti-CD20 antibody immunotherapy
J Uchida, Y Hamaguchi, JA Oliver, JV Ravetch… - The Journal of …, 2004 - rupress.org
Anti-CD20 antibody immunotherapy effectively treats non-Hodgkin's lymphoma and
autoimmune disease. However, the cellular and molecular pathways for B cell depletion …
autoimmune disease. However, the cellular and molecular pathways for B cell depletion …
Antibody isotype-specific engagement of Fcγ receptors regulates B lymphocyte depletion during CD20 immunotherapy
Y Hamaguchi, Y Xiu, K Komura… - The Journal of …, 2006 - rupress.org
CD20 monoclonal antibody (mAb) immunotherapy is effective for lymphoma and
autoimmune disease. In a mouse model of immunotherapy using mouse anti–mouse CD20 …
autoimmune disease. In a mouse model of immunotherapy using mouse anti–mouse CD20 …
Fcγ receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity
TF Tedder, A Baras, Y Xiu - Springer seminars in immunopathology, 2006 - Springer
Immunotherapy using Rituximab, an unconjugated CD20 monoclonal antibody, has proven
effective for treating non-Hodgkin's lymphoma and autoimmune disease. CD19 antibody …
effective for treating non-Hodgkin's lymphoma and autoimmune disease. CD19 antibody …
Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents
MS Cragg, MJ Glennie - Blood, 2004 - ashpublications.org
Despite the success of anti-CD20 monoclonal antibody (mAb) in the treatment of lymphoma,
there remains considerable uncertainty about their mechanism (s) of action. Here, we show …
there remains considerable uncertainty about their mechanism (s) of action. Here, we show …
Regulatory B cell production of IL-10 inhibits lymphoma depletion during CD20 immunotherapy in mice
M Horikawa, V Minard-Colin… - The Journal of …, 2011 - Am Soc Clin Investig
Current therapies for non-Hodgkin lymphoma commonly include CD20 mAb to deplete
tumor cells. However, the response is not durable in a substantial proportion of patients …
tumor cells. However, the response is not durable in a substantial proportion of patients …
The impact of Fc engineering on an anti-CD19 antibody: increased Fcγ receptor affinity enhances B-cell clearing in nonhuman primates
J Zalevsky, IWL Leung, S Karki, SY Chu… - Blood, The Journal …, 2009 - ashpublications.org
CD19, a B cell–restricted receptor critical for B-cell development, is expressed in most B-cell
malignancies. The Fc-engineered anti-CD19 antibody, XmAb5574, has enhanced Fcγ …
malignancies. The Fc-engineered anti-CD19 antibody, XmAb5574, has enhanced Fcγ …
The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice
Y Hamaguchi, J Uchida, DW Cain… - The journal of …, 2005 - journals.aai.org
Although anti-CD20 immunotherapy effectively treats human lymphoma and autoimmune
disease, the in vivo effect of immunotherapy on tissue B cells and their subsets is generally …
disease, the in vivo effect of immunotherapy on tissue B cells and their subsets is generally …
Triggering Fcα-receptor I (CD89) recruits neutrophils as effector cells for CD20-directed antibody therapy
B Stockmeyer, M Dechant, M van Egmond… - The Journal of …, 2000 - journals.aai.org
CD20 Abs induce clinical responses in lymphoma patients, but there are considerable
differences between individual patients. In 51 Cr release assays with whole blood as effector …
differences between individual patients. In 51 Cr release assays with whole blood as effector …
Therapeutic efficacy of FcγRI/CD64-directed bispecific antibodies in B-cell lymphoma
J Honeychurch, AL Tutt, T Valerius… - Blood, The Journal …, 2000 - ashpublications.org
CD64 (FcγRI) receptors represent highly potent trigger molecules for activated
polymorphonuclear cells (PMN) and mediate lysis of a range of tumors in the presence of …
polymorphonuclear cells (PMN) and mediate lysis of a range of tumors in the presence of …